Background {#Sec1}
==========

Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by persistent impairment in social communication and interaction and restricted and repetitive patterns of behavior, interests, or activities \[[@CR1]\]. There is evidence that one in every 132 to one in every 68 individual suffers from ASD \[[@CR2], [@CR3]\]. According to a recent meta-analysis, ASD accounted for 7.7 million disability adjusted life years in 2010 and was the leading mental cause of disability in children under five in terms of years lived with disability \[[@CR2]\].

While in the majority of cases of the exact etiology of ASD remains unknown, novel technologies and large population-based studies have provided new insight into the risk architecture of ASD and the possible role of environmental factors in etiology \[[@CR4]\]. Twin studies provide a unique platform to study the relative contribution of genetic and (shared and non-shared) environmental factors to the variability of a certain trait or disorder. Dizygotic (DZ) twins on average share 50% of their genes, and monozygotic (MZ) twins share 100% of their genes. Twins are matched for many characteristics including age, in utero and family environment, and various aspects of early and late development. Taken together, these features allow for estimating heritability (phenotypic variation that is attributable to the genotypic variation) of ASD by taking into the account its covariance within MZ and DZ twins \[[@CR5]\]. Earlier twin studies suggested heritability as high as 80--90% for ASD with little contribution from the environment \[[@CR4], [@CR6], [@CR7]\]. However, according to recent evidence, up to 40--50% of variance in ASD liability is determined by environmental factors \[[@CR8]--[@CR13]\]. Newer studies of monozygotic twins have yielded concordance rates of \<50%, with lower concordance for dizygotic twins, suggesting that both genes and environment play roles in the development of ASD \[[@CR4], [@CR14]--[@CR16]\]. Given the vulnerability of the developing brain to environmental factors, the causative association between environmental factors and ASD is biologically plausible \[[@CR17]\]. Furthermore, historical proof-of-concept evidence shows a causal relation between specific environmental risk factors such as thalidomide and misoprostol and ASD \[[@CR17]--[@CR20]\].

In the present paper, we provide an evidence-based review of the current knowledge about environmental risk factors in ASD using findings from published systematic reviews and meta-analyses. Although reviewing systematic reviews and meta-analyses inherently focuses on the most well-studied findings, it automatically excludes the studies that are published after the included reviews or that, for any reason, are not systematically reviewed. It is therefore important to keep in mind that the purpose of this review is not to review all possible environmental risk factors, but rather to provide a wide view of the evidence landscape in epidemiology of risk factors for ASD.

Methods {#Sec2}
=======

We searched Pubmed since inception until December 2016 for ((autis\*) or ("pervasive developmental disorder") or ("Asperger")) and ("systematic review" or "meta-analysis"). We extracted the following for meta-analyses: number of studies, study design, imprecision (\>0.25 difference between effect estimates and their upper or lower confidence bound for dichotomous variables and \>0.5 difference for continuous outcomes), inconsistency (presence of heterogeneity *I* ^2^ \> 50% or *P* value of heterogeneity test \< 0.10), magnitude of association (relative risk estimate \<2.0 small, 2.0--5.0 medium, \>5.0 large), publication bias, and indirectness (that is measuring exposure based on population-level assessment) \[[@CR21], [@CR22]\]. Imprecision reflects how wide or narrow the confidence interval is: the narrower the confidence interval, the greater the precision. Heterogeneity or inconsistency refers to the degree of between-study variability in a meta-analysis.

A meta-analysis provides higher quality of evidence for an association if it yielded precise, consistent, direct, and strong association without publication bias. For systematic reviews, we narratively summarized the authors' conclusion in a separate table (because quantitative assessment was not possible). For each potential risk factor, the latest systematic review or meta-analysis was considered unless indicated otherwise (See Additional file [1](#MOESM1){ref-type="media"}: Table S1 for more details).

Results {#Sec3}
=======

A total of 663 citations were found. One additional relevant reference was found through manual search of the reference list in the remaining papers. Of these, 584 records were excluded by title or abstract. Of the remaining 80 studies, 32 references (9 qualitative systematic reviews and 23 meta-analyses) were included for the purpose of the review (See Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Table S1 for the details on the excluded studies).

Figure [1](#Fig1){ref-type="fig"} and Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} summarize the findings of meta-analyses and systematic reviews respectively. Below, we present the evidence for nine different groups of risk factors (including about 100 individual risk factors), namely advanced parental age, pregnancy-related factors, prenatal medication, maternal diseases, nutrition, environmental toxins, vaccine, maternal smoking, and maternal immigration.Fig. 1The association between several environmental factors and autism spectrum disorders; C/S, caesarian section; GDM, gestational diabetes mellitus; HDoP, hypertensive disease of pregnancy; PROM, premature rupture of membrane; SSRI, selective serotonin reuptake inhibitor Table 1Summary of meta-analyses of environmental risk factors for autism spectrum disordersRisk factor \[ref\], yearNo. of studiesStudy designEstimatesPrecisionConsistencyDirectnessPublication biasAdvanced parental age \[[@CR23]\], 2017• Highest paternal age category204 cohort; 16 case-control++−+Absent• Highest maternal age category194 cohort; 15 case-control++−+AbsentLabor \[[@CR25]\], 2011• Prolonged labor9NA+/−−−+Absent• Induced or augmented labor8NA+/−−−+Absent• Precipitous labor5NA+/−−−+Absent• Premature rupture of membranes7NA+/−−++AbsentDelivery options \[[@CR25]\], 2011• Cesarean section \[[@CR29]\], 2015216 Cohort; 15 case-control++−+Absent• Emergency cesarean4NA+/−−−+Absent• Elective cesarean2NA+/−−−+Absent• Delivery anesthesia7NA+/−−++Absent• General anesthesia3NA+/−−++Absent• Assisted vaginal delivery14NA+/−+++Absent• Forceps7NA+/−−++Absent• Vacuum extraction2NA−/+−−+AbsentConditions at birth \[[@CR25]\], 2011• Abnormal presentation15NA+−−+Absent• Breech presentation4NA+−++Absent• Cord complications14NA+−++Absent• Fetal distress4NA+−++Absent• Birth injury or trauma6NA++−++Absent• Twins or multiple birth10NA+−−+AbsentMaternal hemorrhage \[[@CR25]\], 20114NA++−++AbsentTiming of birth \[[@CR25]\], 2011• January through March4NA+/−+++Absent• April through June4NA+/−−−+Absent• July through September4NA+/−+++Absent• October through December4NA−/+−−+Absent^b^• Fall3NA−/+−−+Absent• Winter3NA−/+−−+Absent• Spring3NA−/+−−+Absent• Summer3NA++++AbsentBirth spacing (ref ≥36 m) \[[@CR30]\], 201673 cohort; 3 cross-sectional; 1 case-control• \<12 months5NA+−−+NC• 12--23 months5NA+/−−−+NC• 24--35 months5NA−/+−−+NCBirth spacing (ref 24--59 m) \[[@CR30]\], 2016• \<12 months4NA+−−−NC• 12--23 months4NA+−−−NC• \>60 months4NA+−−−NCGestational age \[[@CR25]\], 2011• Postterm14NA+/−−−+Absent• Preterm17NA+/−−−+Absent• \>4 weeks preterm2NA+/−−++AbsentBirth weight \[[@CR25]\], 2011• Birth weight \<2500 g15NA+−−+Absent• Birth weight \<2000 g2NA+/−−−+Absent• Birth weight \<1500 g3NA++−++Absent• Birth weight \>4000 g6NA+/−−++Absent^b^Neonatal clinical and medical conditions \[[@CR25]\], 2011• Meconium aspirated3NA+++−++Absent^b^• Neonatal infection2NA−/+−++Absent• Elevated temperature2NA+/−−−+Absent• ABO or Rh incompatible5NA++−++Absent• Hyperbilirubinemia or jaundice14NA+/−−−+Absent• Jaundice4NA+/−−++Absent• Hyperbilirubinemia6NA+−−+Absent• Phototherapy2NA+/−−−+Absent• Medical intervention in the first month7NA+/−−−+AbsentImpaired gas exchange \[[@CR28]\], 2016• Acidosis at birth22 population-based++++Absent• Apgar at 1 min \<633 population-based++−++Absent• Apgar at 1 min \<733 population-based++++Absent• Apgar at 5 min \<766 population-based+−++Absent• Apgar at 5 min \<832 population-based; 1 clinic-based++−++Absent• Apgar at 5 min \<921 population-based; 1 clinic-based+/−−++Absent• Apnea/delayed crying53 population-based; 2 clinic-based++−−+Absent• Respiratory distress126 population-based; 6 clinic-based++++Absent• Ventilation/O2 treatment94 population-based; 5 clinic-based++−++Present^c^• Undefined hypoxia/asphyxia92 population-based; 7 clinic-based++−−+AbsentMother born in another country \[[@CR24]\], 20095NA+/−−−+AbsentPrevious fetal loss \[[@CR24]\], 200913NA+/−−++AbsentBirth order/parity \[[@CR24]\], 2009• 1 pregnancy increase8NA−/++−+Absent• 1st vs. not 1st11NA+/−+−+Absent• 1st vs. 2nd4NA+/−−−+Absent• 1st vs. 2nd or 3rd6NA+/−−−+Absent• 1st vs. 3rd+4NA++++Absent• 1st vs. 4th+6NA−/+−−+Absent• 1st or 4th vs. 2nd or 3rd5NA+/−−−+Absent• 4th vs. 2nd or 3rd5NA+/−−++AbsentMaternal illness/conditions \[[@CR24]\], 2009• Maternal proteinuria3NA−/+−++Absent• Toxemia/preeclampsia, hypertension, swelling25NA+/−−−+Absent• Maternal diabetes \[[@CR31]\], 2014123 cohort++++Absent9 case-control+−++Absent• Maternal infection \[[@CR33]\], 2016152 cohort; 13 case-control++−+Absent• Bacterial infection \[[@CR33]\], 20164NA++−+Absent• Viral infection \[[@CR33]\], 20164NA+/−−−+Absent• Influenza \[[@CR33]\], 20163NA+/+−+Absent• Genitourinary infection \[[@CR33]\], 20168NA++++Absent• Skin infection \[[@CR33]\], 20163NA+−++Absent• Gastrointestinal infection \[[@CR33]\], 20163NA+/−−++Absent• Respiratory infection \[[@CR33]\], 20167NA+/−+++Absent• Family history of autoimmune disease \[[@CR35]\], 2015113 cohort; 6 case-control; 2 cross-sectional++−+Present^c^• Maternal autoimmune disease \[[@CR34]\], 2016109 case-control; 1 cohort++++Absent• Rubella3NA+/−−++Absent• Fever4NA+/−−++Absent• Nausea vomiting6NA+/−−−+Absent• Physical injury accident5NA+/−−++Absent• Any illness4NA+/−−++AbsentMaternal weight \[[@CR32]\], 2016• Maternal underweight5All cohort+/−+++Absent• Maternal overweight5All cohort++++Absent• Maternal obesity76 cohort; 1 case-control+−−+AbsentPrenatal visit \[[@CR24]\], 20092NA−/+−−+AbsentBleeding \[[@CR24]\], 200919NA+−−+Absent• 1st trimester2NA+/−−++Absent• 2nd trimester2NA−/+−++Absent• 3rd trimester2NA−/+−++AbsentPlacental abnormalities \[[@CR24]\], 20098NA+/−−++Absent• Placenta previa2NA+/−−++Absent• Placenta abruption2NA−/+−++Absent• Placental infarcts2NA+/−−++AbsentHigh maternal weight gain during pregnancy \[[@CR24]\], 20095NA−/+−−+AbsentMaternal smoking \[[@CR39]\], 2015154 cohort; 11 case-control+/−+−+Absent• Prenatal8NA+/−+−+NC• Neonatal2NA−+++NC• Postnatal5NA+−−+NCMedication use during pregnancy \[[@CR24]\], 200915NA+−++• Anticonvulsants2NA+/−−++Absent• SSRIs \[[@CR38]\], 201683 cohort; 5 case-control+−++Absent• Antidepressants \[[@CR112]\], 20143All case-control+/−−−+AbsentThimerosal \[[@CR47]\], 201491 retrospective and 2 prospective cohort; 6 case-control+/−++Mixed^a^Present^d^Inorganic mercury \[[@CR47]\], 201433 case-control+−++NCVaccination \[[@CR52]\], 2014105 cohort−/++++Absent5 case-control−+−+AbsentMMR vaccine \[[@CR52]\], 20143All cohort−/++++AbsentMetal exposure \[[@CR48]\], 2014• Hg through vaccine \[[@CR52]\], 20142Both retrospective cohort+/−• Hair Hg7All case-control+/−−NC+NC• Hair Cd4All case-control−/+−NC+NC• Hair Pb5All case-control+−NC+NC• Hair Cu4All case-control+/−−NC+NC• Hair Se3All case-control−/+−NC+NC• Hair Li3All case-control−/+−NC+NC• Zn/Cu \[[@CR113]\], 201511All case-control−/+−−+AbsentNutritional intake \[[@CR40]\], 2013• Zinc \[[@CR41]\], 201612All case-control−+−+Absent• Calcium8NA−−−−−Absent• Carbohydrates7NA−/+−−−Absent• Energy6NA−/+−−−Absent• Fiber6NA+/−−−−Absent• Iron7NA+/−−−−Absent• Protein7NA−−−−−Absent• Total fat6NA+/−−−−Absent• Vitamin A6NA−/+−−−Absent• Vitamin C7NA−/+−−−Absent• Vitamin D \[[@CR42]\], 201611All case-control−−−−−+Possible• Vitamin E5NA+/−−−−AbsentAir pollution \[[@CR46]\], 2016• PM10 (every 10 μg/m^3^)65 case-control; 1 cohort++−−NC• PM2.5 (every 10 μg/m^3^)33 case-control++−−NC• O3 (every 10 μg/m^3^) \[[@CR114]\], 201422 case-control+++−NC+/−, positive but statistically non-significant effect estimates; +/, marginally positive; −/+, negative but statistically non-significant effect estimates; +, positive statistically significant effect estimates (number of + corresponds to the strengths of the association); −, negative statistically significant effect estimates (number of − corresponds to the strengths of the association)^a^Only direct −/+^b^Begg's test was not significant; Egger's test was significant^c^Adjusted for bias +^d^Adjusted for bias −/+*NA* not available, *NC* not calculated Table 2Summary of systematic reviews of environmental risk factors for autism spectrum disordersRisk factorsDesignSummary of findingsCommentsMaternal immigration \[[@CR53]\], 201510 population-basedThe adjusted results showed higher rates of ASD if children had migrant mothers (2.69%) compared with children of non-migrant mothers (0.91%). Six out of ten studies found that giving birth postmaternal migration significantly raised risks of ASD, with the exception of children born to Hispanic migrant mothers who had lower rates of ASD (compared to all other migrant groups)A meta-analysis by another group supports these findingsPreconceptional chemical exposure \[[@CR49]\], 20143 case-controlAll studies showed an increased rate of ASD in children whose parents were exposed to chemicalsThe studies were limited by retrospective design and small sample sizesPesticide exposure during pregnancy \[[@CR49]\], 20141 retrospective case-control; 3 prospective cohortAll showed an increased rate of ASD in children with gestational exposure to chemicals including two prospective studies of organophosphatesThe studies provide enough evidence to justify larger studies of pesticide exposure in ASDPesticide exposure during childhood \[[@CR49]\], 20141 retrospective cross-sectional; 1 prospective cohort; 1 computer modelOne study showed an association between organophosphate exposure; one between DDE exposure and ASD, and one between phosphine exposure and ASDAir pollution during prenatal period \[[@CR49]\], 20146 retrospectiveAll studies showed an increased rate of ASD associated with air pollution (with particulate matter in three studies and with NO2 in two studies)A meta-analysis of four prospective European cohorts showed no association between air pollution and ASDAir pollution during childhood \[[@CR49]\], 20143 retrospective case-controlAll studies showed some association between air pollution and ASD (association with NO2 is replicated in two studies)Exposure to other chemicals \[[@CR49]\], 20142 prospective cohort; 4 retrospective case-controlNo effect in prospective studies; retrospective studies found some effects for solvents and other toxicantsRetrospective studies used questionnairesToxic waste sites \[[@CR49]\], 20142 case series, ecologicalAssociation of Superfund site with ASD in both studiesWater pollutant \[[@CR49]\], 20142 ecologicalNo association between water chlorination and ASD in either studiesHeavy metals \[[@CR49]\], 20148 ecological7 studies showed association between Hg and ASD, one showed no associationEcological studies are limited by indirect measures of exposureIn-house flooring \[[@CR49]\], 20141 cohortPolyvinyl chloride vs. wood floor increases the risk of ASDMercury levels \[[@CR49]\], 201429 case-control12 studies with elevation in at least one tissue in patients with ASDStudies measuring levels of heavy metals were limited by cross-sectional design and small sample size. Furthermore, it is unclear how much cross-sectional measurements of metals in the body reflect the causal effect of such exposures on ASD risk.Lead levels \[[@CR49]\], 201425 case-control11 studies with elevation in at least one tissue in patients with ASDCadmium levels \[[@CR49]\], 201414 case-control5 studies with elevation in at least one tissue in patients with ASDAluminum levels \[[@CR49]\], 201411 case-control3 studies with elevation in at least one tissue in patients with ASDArsenic \[[@CR49]\], 20148 case-control5 studies with elevation in at least one tissue in patients with ASDNickel \[[@CR49]\], 20143 case-control2 studies with elevation in at least one tissue in patients with ASDUranium levels \[[@CR49]\], 20142 case-control1 studies with elevation in at least one tissue in patients with ASDTin levels \[[@CR49]\], 20141 case-control1 studies with elevation in at least one tissue in patients with ASDHeavy metals and severity \[[@CR49]\], 20147 correlational studiesAll studies showed some correlation between ASD severity and heavy metal levels (particularly Hg and Pb)These studies suggest a dose-response relationship between metal exposure and ASD.Heavy metals and chelation \[[@CR49]\], 201412 uncontrolled studiesAll showed improvement in symptoms of ASD following chelation treatmentThe studies are limited by lack of the control groupUrine porphyrin studies \[[@CR49]\], 20144 case-series; 7 case-controlAll studies showed some association with severity, prediction, or oxidative stressThe studies are limited by retrospective natureSolvents, pesticides, and PCB \[[@CR49]\], 20142 case series; 2 case-controlCase series showed levels above normal adult range for children with ASD; case-control studies showed no association between PCB and ASDThe studies were limited by either lack of proper control group or small sample sizePhthalate \[[@CR51]\], 20162 cohort; 3 case-controlThree studies showed association between phthalate exposure and ASD; two studies showed no associationPBDE \[[@CR49]\], 20141 case-controlPBDE resulted in higher activation of immune response in patients with ASDValproate \[[@CR37]\], 20141 population-based prospective; 2 prospective case series; 1 retrospectiveAll studies found significant and strong association between prenatal valproate exposure and ASDThe association between valproate and ASD is likely to be causal given the strength of association and evidence for biological plausibilityFolic acid \[[@CR44]\], 201611 studiesThe findings were inconsistent; some studies provide support for the beneficial effect of folic acid on risk of ASD, whereas others show the opposite effectObservational studies were limited by self-report, whereas RCTs were limited by use of multivitaminCamel milk \[[@CR115]\], 20162 small short-term RCTsResults showed beneficial effects on ASD symptomsIt is unclear whether this benefit is clinical and whether it extends to longer period of treatmentCasein and gluten-free diet \[[@CR116]\], 201416 studiesFindings are inconsistentStudies with positive findings were mostly of low qualityOmega-3 \[[@CR43]\], 20112 RCTsStudies found no evidence for beneficial effects of omega-3 on ASD symptomsAssisted reproductive technologies \[[@CR36]\], 20132 cohort; 5 case-control3 studies showed positive association between ART and ASD, 3 studies showed no association, and 1 study showed a negative association between ART and ASD. The authors concluded that at present, no evidence supports the association between ART and ASDThere are several sources of heterogeneity such as study design, exposure definition, data source, and confounders.*ART* assisted reproductive technology, *ASD* autism spectrum disorder, *DDE* dichlorodiphenyldichloroethylene, *NO2* nitrogen dioxide, *RCT* randomized controlled trial

Advanced parental age {#Sec4}
---------------------

Wu et al. \[[@CR23]\] performed a meta-analysis of 27 studies on association between advanced parental age and ASD. They showed that every 10-year increase in maternal and paternal age increases the risk of ASD in the offspring by 18 and 21% respectively. Furthermore, compared with the reference age group, oldest age category (in both mothers and fathers) was associated with a small but significant and precise increase in risk of ASD in the offspring.

Pregnancy-related complications and conditions {#Sec5}
----------------------------------------------

Several systematic reviews and meta-analyses have summarized the evidence on the association between pregnancy complications and ASD \[[@CR24]--[@CR27]\] (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Gardener et al. \[[@CR24], [@CR25]\] carried out two comprehensive reviews of prenatal and perinatal risk factors for ASD. They found statistically significant pooled estimates with small effect size for abnormal presentation, breech presentation, cord complications, fetal distress, multiple births, low birth weight, small for gestational age, congenital malformations, hyperbilirubinemia, and earlier birth (first vs. third born). Evidence suggested a medium yet imprecise effect size for five risk factors including maternal hemorrhage, Rh or ABO incompatibility, birth injury or trauma, birth weight \<1500 g, and feeding difficulties at birth. Large and imprecise effect sizes were observed for neonatal anemia and meconium aspiration (Table [1](#Tab1){ref-type="table"}).

A meta-analysis by our group has specifically addressed the link between proxies of impaired gas exchange and ASD \[[@CR28]\]. Out of ten proxies that were analyzed, the effect size was medium (and imprecise) for apnea/delayed crying, undefined hypoxia/asphyxia, 1-min Apgar score \<6, 5-min Apgar score \<8, and O2 treatment, and small and imprecise for the rest (Table [1](#Tab1){ref-type="table"}).

Curran et al. \[[@CR29]\] reviewed 21 studies of the association between cesarean section (C/S) and ASD. They found a 36% increase in the risk of ASD following C/S that was reduced after adjusting for confounders or limiting the analysis to population-based studies and was absent in the cohort studies. The effect size was small, precise, and inconsistent. Moreover, they showed that estimates were lower for elective C/S compared with emergency C/S (Table [1](#Tab1){ref-type="table"}).

In a systematic review of seven studies, Conde-Agudelo and colleagues found that birth spacing \<12 months and \>60 months are associated with a significantly increased risk of ASD (Table [2](#Tab2){ref-type="table"}) compared to the birth spacing in the middle range. The estimates were of small magnitude, inconsistent, and imprecise. However, the included studies were generally of high quality. The estimates were slightly larger for the former subtype autistic disorder \[[@CR30]\] (Table [1](#Tab1){ref-type="table"}).

Xu and colleagues conducted a meta-analysis on the association between maternal diabetes and ASD in the offspring. For cohort studies, they found a 74 and 43% (both small effect sizes) increase in risk for pregestational and gestational diabetes respectively (Table [1](#Tab1){ref-type="table"}) \[[@CR31]\]. As expected, slightly higher odds ratios were observed for case-control studies. In a meta-analysis of seven studies, Wang and colleagues \[[@CR32]\] showed that overweight and obese mothers (but not underweight mothers) have an increased risk of ASD by about 28 and 36% respectively. The increased risk for overweight mothers was precise and consistent, whereas for obese mothers, it was imprecise and inconsistent (Table [1](#Tab1){ref-type="table"}).

Jiang et al. \[[@CR33]\] systematically reviewed of maternal infection during pregnancy and risk of ASD. Their most important findings include a small but significant increase in risk of ASD after maternal bacterial (18%) and genitourinary infection (9%). The risk was precise but inconsistent. They also found a small increase in ASD after maternal flu that was precise, inconsistent, and marginally significant.

A meta-analysis of ten studies by Chen et al. \[[@CR34]\] found that maternal autoimmune disease is associated with a small but significant, precise, and consistent increase in risk of ASD in the offspring. Similarly, a meta-analysis of 11 studies by Wu et al. \[[@CR35]\] showed that family history of autoimmune illness increased the risk of ASD. The effect size was small and inconsistent but precise. In subgroup analysis, family history of autoimmune thyroid disease, diabetes, psoriasis, and rheumatoid arthritis were associated with an average 49--64% increase in risk of ASD in the offspring (Table [1](#Tab1){ref-type="table"}).

Conti et al. \[[@CR36]\] conducted a systematic review of the association between assisted reproductive technology (ART) and risk of ASD. Three out of seven studies suggested an association between ART and ASD, but these studies were of low quality. On the other hand, high-quality studies showed no association between ART and risk of ASD (Table [2](#Tab2){ref-type="table"}).

Medication use during pregnancy {#Sec6}
-------------------------------

Gentile \[[@CR37]\] systematically reviewed the evidence for the association between maternal valproate use (a medication primarily used for epilepsy and bipolar disorder) and ASD in the offspring. Studies with both prospective and retrospective design provided strong evidence for the association of maternal valproate use and ASD as well as several other neurodevelopmental outcomes. Valproate was associated with poorer neurodevelopment than other antiepileptic drugs. Furthermore, the association seemed to be dose-related and robust to adjustment for several confounders including seizure attacks during pregnancy and maternal intelligence quotient (Table [2](#Tab2){ref-type="table"}).

The association between maternal antidepressant use during pregnancy and ASD is more controversial. Kobayashi et al. \[[@CR38]\] quantitatively reviewed five case-control and three cohort studies of maternal selective serotonin reuptake inhibitor (SSRI) use in pregnancy and the risk of ASD in the offspring. They found a 50% increase in risk of ASD of mothers who took SSRIs during pregnancy; the estimate was imprecise but consistent. However, when the authors conducted a sensitivity analysis comparing SSRI-exposed group to SSRI-non-exposed group in mother with psychiatric conditions, they found no significant increase in risk of ASD in the offspring. Based on this evidence, the authors concluded that the relation between SSRI and ASD finding is largely due to confounding by indication (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).

Maternal smoking {#Sec7}
----------------

A meta-analysis of 15 studies by Rosen et al. \[[@CR39]\] found precise (but inconsistent) evidence that there was no association between maternal smoking and risk of ASD in the offspring. The lack of association was unaffected by adjustment for socioeconomic status and parental psychiatric history and was consistent in assessments carried out during pregnancy and at birth. For postnatal assessment of prenatal smoking, there was a slight and imprecise increase in risk, which might reflect a recall bias (Table [1](#Tab1){ref-type="table"}).

Nutritional factors {#Sec8}
-------------------

Several studies have tried to establish an association between nutritional elements such as folic acid or vitamin D and risk for ASD. However, many of those studies are fundamentally limited by the fact that they have assessed the deficiency and/or the efficacy of supplementing these nutrients after developing ASD. Therefore, one should be very cautious about causal interpretation of the findings in those studies.

A meta-analysis by Sharp et al. \[[@CR40]\] showed significantly lower protein and calcium intake in children with ASD. However, the estimates were imprecise, inconsistent, and indirect. Another meta-analysis of 12 studies by Babaknejad et al. \[[@CR41]\] showed significantly lower zinc levels in children with ASD. Wang et al. \[[@CR42]\] performed a meta-analysis of 11 studies of the association between vitamin D and ASD. They found significantly lower levels of serum 25-hydroxy vitamin D in subjects with ASD than those in controls (Table [2](#Tab2){ref-type="table"}). The pooled effect size was large, but inconsistent and imprecise. Of note, the number of studies that investigated vitamin D levels in maternal blood during pregnancy was too small to allow for a meta-analysis.

Systematic reviews of the association between omega-3 fatty acids and ASD have mainly focused on interventional studies. In a Cochrane review, only two small randomized trials met the eligibility criteria \[[@CR43]\]. The authors found no evidence of a beneficial effect of omega-3 in patients with ASD (Table [2](#Tab2){ref-type="table"}).

Castro et al. \[[@CR44]\] systematically reviewed the evidence for folic acid involvement in risk of ASD. The authors found some evidence for the association between folate deficiency and ASD and ASD-like traits. However, the findings were inconsistent and were limited by the self-report in the majority of studies (Table [2](#Tab2){ref-type="table"}). Another systematic review suggested that folate deficiency might interact with certain polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene to increase risk of ASD \[[@CR45]\].

There are reports of other dietary interventions such as camel milk and casein and gluten-free diet in ASD, but studies of such interventions have generally been short term and of low quality.

Exposure to toxins {#Sec9}
------------------

Studies of toxic exposure have been largely limited by indirect and cross-sectional methods of exposure measurement. Quantitative systematic reviews have been performed on air pollution, thimerosal (ethylmercury), inorganic mercury, and hair levels of heavy metals. In a meta-analysis, Lam and colleagues \[[@CR46]\] found a small but significant and precise association between prenatal exposure to particulate matters and risk of ASD. However, the risk was inconsistent across studies and the exposure was measured via indirect methods (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Of note, the risk was substantially larger for particulate matter \<2.5 μm compared to those of \<10 μm.

In a meta-analysis of nine studies, Yoshimasu et al. \[[@CR47]\] found precise and consistent evidence for lack of association between childhood thimerosal exposure and ASD. The lack of association was consistent in pooled analysis of the adjusted estimates, studies of anti-RhD antibody treatment, and studies of direct thimerosal exposure. In a meta-analysis of three case-control studies, the same authors reported a 60% increase in risk of ASD following higher level of inorganic mercury exposure. Based on their findings, the authors suggested that early life exposure to mercury by vaccination did not increase the risk of ASD, whereas exposure to inorganic mercury in the environment might be associated with an increased risk of ASD (Table [1](#Tab1){ref-type="table"}).

De Palma and colleagues \[[@CR48]\] performed a meta-analysis of studies that compared hair concentration of heavy metals between patients with ASD and controls. Their meta-analyses found little evidence for an association between hair metal concentration of mercury, copper, cadmium, selenium, and chromium. They did find significantly higher levels of lead in the hair of patients with ASD than those of controls. However, the estimates for lead were imprecise and inconsistent across studies and were disproportionately affected by an outlier study (Table [1](#Tab1){ref-type="table"}).

Rossignol et al. \[[@CR49]\] carried out the most comprehensive systematic review of environmental toxins in ASD. The authors evaluated two groups of studies based on direct or indirect assessment of exposure. Studies with indirect assessment of exposure were generally of ecological or retrospective nature and overall provide lower grade of evidence as compared with studies of more direct exposure. Most of studies of indirect exposure have shown an association between one or more environmental toxin exposures and ASD, even though the results have been inconsistent. The most consistent finding among this group of studies was for an association between environmental mercury exposure and ASD in seven of eight ecological studies (Table [2](#Tab2){ref-type="table"}).

Rossignol and colleagues \[[@CR49]\] also made an exhaustive effort of synthesizing the evidence on the relationship between direct biomarkers of toxic exposure and ASD. Systematic review of five metals (mercury, lead, cadmium, aluminum, and arsenic) contained eight or more case-control studies. Studies measured metal concentrations in blood, hair, tooth, urine, or brain. For all metals but arsenic, more than half of studies showed no elevation in any of the measurement in patients with ASD compared with control subjects. The authors further identified seven studies that reported an association between heavy metal concentration (mostly mercury and lead) and severity of ASD. Furthermore, 12 studies described improvement in symptoms of ASD following chelation therapy. However, none of these studies used a placebo arm and are therefore difficult to interpret. Importantly, a recent Cochrane systematic review found no evidence for the beneficial effect of chelation therapy on ASD \[[@CR50]\] (Table [2](#Tab2){ref-type="table"}).

Studies of the association between endocrine-disrupting chemicals and ASD are scarce. Rossignol et al. \[[@CR49]\] reviewed two case-control studies of polychlorinated biphenyls (PCB) and found no association between PCB and risk of ASD, whereas Jeddi et al. \[[@CR51]\] found that three out of five studies of phthalate exposure showed a significant association between phthalate exposure and risk of ASD (Table [2](#Tab2){ref-type="table"}).

Vaccination {#Sec10}
-----------

Taylor et al. \[[@CR52]\] performed a meta-analysis of studies that investigated the association between childhood vaccines and ASD. The authors found no evidence for a higher risk of ASD in subjects who are vaccinated. Their results were precise, consistent (except for case-control studies), and robust to study design or subtypes of ASD. Indeed, their findings were suggestive of a protective effect of vaccines on risk of childhood autism in case-control studies. Given the concerns over the association between ASD and the mumps, measles, and rubella (MMR) vaccine, the authors conducted a separate meta-analysis of three studies of MMR vaccine and ASD and found a non-significant decrease in risk of ASD following MMR vaccination (Table [1](#Tab1){ref-type="table"}).

Maternal immigration {#Sec11}
--------------------

In a meta-analysis of five studies, Gardener et al. \[[@CR24]\] found imprecise and inconsistent association between maternal immigration and ASD. Restricting the studies to Nordic countries, they found a significant small effect size for the association between immigration and ASD. In a systematic review of the association between maternal immigration and risk of ASD, Crafa and Varfa \[[@CR53]\] found ten eligible studies. The authors observed significantly higher risk of ASD in the immigrants in three studies, whereas five studies showed no difference between immigrant and non-immigrant mothers, and two studies showed significantly lower risk of ASD in immigrants than that in non-immigrants. After controlling for the effects of different sample sizes and ethnic backgrounds, the results showed higher rates of ASD in children of immigrant mothers (2.69%) compared with those in children of non-migrant mothers (0.91%). Six out of ten studies found that giving birth postmaternal migration significantly increased the risk of ASD, with the exception of children born to Hispanic migrant mothers who had lower rates of ASD (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).

Possible mechanisms behind the association between environmental risk factors and ASD {#Sec12}
-------------------------------------------------------------------------------------

A fundamental question about the association between environmental risk factors and ASD is whether the association represents an underlying causality or not. Although evidence in this area is still speculative, here, we briefly review the possible mechanisms of involvement of environmental factors in ASD. It should be emphasized that the mechanisms reviewed here are by no means exhaustive. Furthermore, each environmental factor---if causal---might involve multiple mechanisms and at different levels of etiological pathways to ASD.

Non-causal associations {#Sec13}
-----------------------

A plausible explanation for many of the observed environmental effects of ASD might be that of confounding. For example, the association between several obstetric complications and ASD might be partially confounded by parity, because parity is associated both with the exposure (i.e., birth complications) and the outcome (i.e., ASD) \[[@CR54]\]. Moreover, a substantial proportion of what might be interpreted as causal effect of environment on ASD risk might result from a gene-environment correlation. For example, many genetic conditions that are associated with ASD might also be associated with birth complications. These epiphenomena are observed with higher frequency in children with ASD but are not necessarily causal \[[@CR55]\]. Similarly, the association between maternal SSRI use and ASD might be due to confounding by indication. Given that ASD has a high comorbidity rate with depression, such associations might reflect a shared risk mechanism rather than causality \[[@CR56]\]. Confounding by gene-environment correlation might also account for the association between other risk factors such as maternal immigration and ASD. It has been proposed that fathers with autistic traits are more likely to marry immigrant women \[[@CR57]\].

Genetic and epigenetic-related effects {#Sec14}
--------------------------------------

In addition to gene-environment correlation, environmental factors could interact with genetic components on various levels. It has been suggested that some environmental factors such as certain toxins and vitamin D deficiency increase the risk of gene mutation that in turn can lead to an increased risk of ASD \[[@CR58]\]. Recent evidence shows that a specific polychlorinated biphenyl congener, PCB-95, might modify the number of copy number variations leading to deletion or duplications of 15q11-q13, a genetic cause of ASD \[[@CR59]\]. Maternal obesity modifies the expression of several important genes (such as apolipoprotein D) that are critical to neurodevelopment in utero \[[@CR60]\].

Epigenetic mechanisms are biochemical modifications of DNA or histones that affect gene expression without changing the DNA sequence. Epigenetic mechanisms are thought to be critical in the normal development of the nervous system \[[@CR61]\]. Some environmental risk factors of ASD might affect neurodevelopment through epigenetic mechanisms. For example, valproate, a strong risk factor for ASD, inhibits histone deacetylase and interferes with folic acid metabolism \[[@CR62], [@CR63]\]. Both mechanisms result in significant alterations in epigenetic modifications. Folate deficiency in a background of methylene tetrahydrofolate reductase (MTHFR) gene polymorphism might impair methyl donation and subsequently lead to impaired epigenetic regulation \[[@CR64]\]. Assisted reproductive technology and maternal stress (due to immigration) have also been linked to epigenetic alterations \[[@CR65], [@CR66]\], although the importance of such association with respect to ASD is unknown.

Genetic mechanisms also serve to make the individuals susceptible to the effect of certain environmental risk factors. For example, mutation of Mecp2 gene (the cause of Rett syndrome) and a regulator of the epigenome in neurons causes social deficit in mice with prenatal exposure to the organic pollutant polybrominated diphenyl ethers (PBDE) \[[@CR67]\]. Paraoxonase is an enzyme that metabolizes organophosphate. In a systematic review, Rossignol et al. \[[@CR49]\] reported four studies with decreased PON1 activity and three out of five studies showing a significant association between PON polymorphism and ASD. Similarly, they observed an association between polymorphism of glutathione-S transferase (responsible for detoxification of xenobiotics and heavy metals) and ASD in three of four studies \[[@CR49]\].

Inflammation and oxidative stress {#Sec15}
---------------------------------

ASD is associated with altered immune status, increased oxidative stress, and an active neuroinflammatory process characterized by microglial activation in various parts of the brain \[[@CR68]--[@CR71]\]. A meta-analysis has indicated that concentrations of several pro-inflammatory cytokines such as interleukin-6, interluekin-1, and interferon gamma are increased in patients with ASD compared to those in healthy controls \[[@CR70]\]. It is possible that the association of maternal autoimmune disease with risk of ASD is partly mediated through the effect of maternal inflammatory mediators and autoantibodies on fetal neurodevelopment \[[@CR72], [@CR73]\].

Another meta-analysis has demonstrated an association between ASD and altered metabolism of glutathione, an antioxidant \[[@CR68]\]. Some environmental factors such as lead, mercury, persistent organic pollutants, or perinatal complications might cause a pro-inflammatory state and oxidative damage in the brain and subsequently lead to alterations in neural growth and development \[[@CR69], [@CR74]--[@CR76]\]. Moreover, chemicals like brominated flame retardants might result in mitochondrial toxicity through a variety of mechanisms (including oxidative stress) leading to impaired energy balance in the brain \[[@CR77]\]. Mitochondrial dysfunction has been documented in patients with ASD \[[@CR78]\].

Deth et al. \[[@CR79]\] has made a case for a redox/methylation hypothesis of ASD. According to this hypothesis, in a genetically sensitive individual, environmental toxins (particularly toxic metals) cause significant oxidative stress. This subsequently leads to impaired methylation and alters the capacity for synchronizing neural networks through impaired dopamine D4 receptor function. Impaired methylation also affects epigenetic mechanisms, leading to abnormal gene expression. Both mechanisms (impaired synchronization of neural networks and epigenetic alterations) are closely linked to ASD \[[@CR61], [@CR62], [@CR80]--[@CR82]\].

Hypoxic-ischemic damage {#Sec16}
-----------------------

Evidence shows that perinatal hypoxia and hypercarbia are associated with various neurodevelopmental outcomes including seizure, cerebral palsy, and intellectual disability \[[@CR83], [@CR84]\]. As we mentioned earlier, evidence suggests a role for birth asphyxia-hypoxia in risk for ASD. Lack of oxygen and acidosis associated with hypercarbia alter cell energy metabolism and subsequently lead to cell dysfunction and death \[[@CR83]\]. Immaturity of autoregulatory mechanisms and white matter susceptibility in the neonate are important contributory factors in hypoxic-ischemic brain damage \[[@CR85]\]. Moreover, hypoxic/ischemic insult induces inflammation, oxidative damage, and excitotoxicity all of which can lead to exacerbation of neuronal damage and death \[[@CR85], [@CR86]\]. Regions that are involved in cognitive function such as hippocampus and cortex are commonly injured following neonatal hypoxia \[[@CR87]\]. A recent study has provided insight into the possible mechanism of hypoxic damage with regard to ASD \[[@CR88]\]. The authors examined the role of fragile X mental retardation protein (FMRP) and mammalian target of rapamycin (mTOR) signaling pathway in the pathogenesis of hypoxic-ischemic encephalopathy. Hereditary impairment of FMRP is seen in cases of fragile X syndrome that is a well-recognized cause of ASD. Importantly, the authors observed an overexpression of FMRP between 36 and 39 weeks of pregnancy in the normal brain, which suggested an important physiological role for FMRP in synaptic plasticity during this period. Through comparing brain tissues of newborns with hypoxic-ischemic encephalopathy (HIE) with healthy controls, they found significantly lower FMRP expression in the brain of HIE than healthy controls. Based on these findings, the authors suggested that FMRP disruption might be one of the mechanisms through which hypoxic-ischemic damage is related to ASD.

Endocrine disruption {#Sec17}
--------------------

ASD affects gender differentially. Not only the prevalence of ASD seems to be higher in boys but also the psychopathological, biochemical, and genetic aspects of ASD also appear to be different between males and females \[[@CR89], [@CR90]\]. This gender difference has been attributed to a variety of factors, including diagnostic bias in favor of males, extreme male brain (EMB) theory, and female protective effect (FPE) \[[@CR90], [@CR91]\]. Out of all explanations, EMB might be more related to the scope of our review. EMB theory of ASD builds on an empathizing-systematizing theory of psychological sex differences and suggests that ASD might reflect an extreme male pattern (i.e., more systematizing, less empathizing) \[[@CR92]\]. It has been suggested that the differential effect of testosterone on sexually dimorphic brain regions might be a key mechanism to push the brain beyond that of a typical male and toward an EMB. Therefore, factors that alter hormonal balance (and particularly fetal testosterone) might contribute to risk of ASD. An important class of environmental factors that is capable of altering steroid balance is endocrine-disrupting chemicals. For example, brominated flame retardants are both associated with an increased level of free testosterone and an increased risk of ASD \[[@CR93], [@CR94]\]. Recent studies have shown that chemicals (such as some PCB congeners) that are associated with lower testosterone levels are also associated with lower risk of autistic behaviors \[[@CR93], [@CR95]\].

Another link between endocrine disruptors and ASD is alteration in thyroid function. Several studies have shown evidence of prenatal maternal thyroid dysfunction and ASD in the offspring \[[@CR96], [@CR97]\]. Interestingly, many endocrine-disrupting chemicals that disrupt function of thyroid hormone have also been hypothesized to increase the risk of ASD \[[@CR98]--[@CR102]\].

Neurotransmitter alterations and abnormalities in signaling pathways {#Sec18}
--------------------------------------------------------------------

Abnormalities in glutamate, serotonin, and gamma-aminobutyric acid (GABA) have been linked to ASD \[[@CR103]\]. Although alterations in neurotransmitter pathways can be the end result of many mechanisms we discussed above, some environmental factors interact directly with neurotransmitter pathways. For example, lead disrupts the activity of N-methyl-D-aspartate (NMDA) receptors on both pre- and postsynaptic levels \[[@CR104]\]. Many environmental pollutants have been associated with altered glutamate levels in umbilical cord blood \[[@CR105]\]. Similarly, it has been shown that brominated flame retardants modulate GABA in the developing nervous system \[[@CR106]\].

Some environmental risk factors interact with intracellular signaling pathways and might pave the way to impaired neurodevelopment. Exposure to PCB and PBDE seems to alter calcium-related signaling pathway, leading to alterations in dendritic growth and subsequent abnormalities in neuronal connectivity, a key feature of ASD \[[@CR106], [@CR107]\]. Prostaglandin E2 (PGE2) is an important regulatory element in calcium homeostasis and synaptic plasticity in the developing brain \[[@CR108], [@CR109]\]. Evidence suggests disruption of PGE2 as a possible mechanism for the effect of organic chemicals, inflammation, and infection on risk of ASD \[[@CR109]\].

Limitations of current research {#Sec19}
-------------------------------

Compared to genetic studies of ASD, studies of environmental risk factors are in their infancy. Many previous studies of environmental risk factors have been limited by small sample size, retrospective or cross-sectional design, indirect measurement of exposure, and inability to ascertain exact timing of exposure with relation to a critical neurodevelopmental period. Moreover, for various reasons, most previous studies have not investigated important factors that might explain the heterogeneity of ASD such as differences in risk between males and females, differences between subtypes, and relation of symptom severity to risk factors. Importantly, the definition of ASD is very broad and encompasses multiple subtypes of the disorder, mirroring the etiological heterogeneity of the condition.

As results from large prospective cohorts or birth registries are starting to emerge, more valuable data on environmental risk factors become available. Still, heterogeneity of ASD, indirect measures, lack of a dimensional approach, and diagnostic difficulties make it challenging to draw substantial inferences from these studies. As Mandy and Lai in their state in their recent review, to understand the ASD, we must engage with its complexity and take into the account the substantial heterogeneity of the factors that affect its onset as well as its course \[[@CR110]\]. Studies of environmental risk factors of ASD can tackle this complexity by framing ASD as a developmental psychopathology or a maladaptive response of the individual to its environment. This maladaptive response is shaped by interplay between a multitude of risk and protective factors at various levels and evolves as the result of a dynamic interaction between a person and their environment across the lifespan \[[@CR110]\].

Furthermore, it is difficult to establish causality from observational studies due to possibility of genetic and/or environmental confounding. What is interpreted as an environmental effect might indeed be an epiphenomenon due to gene-environment correlation. Therefore, focus should be on designing studies that strengthen causal inferences of environmental risk by ruling out alternative explanation for the association. Studies that use genetically informed approach (e.g., family-based studies and in vitro fertilization designs) offer a new way to address the challenge of gene-environment correlation \[[@CR111]\]. Moreover, gene-environment interaction and epigenetics of ASD are two areas that are clearly understudied but, as recent evidence shows, could potentially provide a substantial insight into the etiology of ASD.

Conclusions {#Sec20}
===========

In the present paper, we reviewed systematic reviews and meta-analyses of environmental risk factors for ASD. Current evidence suggests that several environmental factors including vaccination, maternal smoking, thimerosal exposure, and most likely ART are unrelated to risk of ASD. Birth complications that are associated with trauma or ischemia and hypoxia have shown strong links to ASD, whereas other pregnancy-related factors such as maternal obesity, maternal diabetes, and C/S have shown a weak association with risk of ASD. Furthermore, factors such as maternal use of SSRI or C/S might be indicative of confounding by indication. The reviews on nutritional elements have yielded limited useful and/or inconclusive information about the beneficial effects of folic acid and omega-3, while vitamin D deficiency seems to be common in children with ASD. The studies on toxic elements have been largely limited by their design, but there is enough evidence for the association between some heavy metals (most important inorganic mercury and lead) and ASD that warrants further investigation. Reviews on the psychosocial risk factors for ASD are scarce, with maternal immigration being the only factor that has shown some association with ASD in systematic reviews. Biological underpinning of environmental risk factors of ASD are debated but might include non-causative association, gene-related effect, oxidative stress, inflammation, hypoxia/ischemia, endocrine disruption, neurotransmitter alterations, and interference with signaling pathways. Future studies of ASD risk factors would benefit from a developmental psychopathology approach, prospective design, precise exposure measurement, reliable timing of exposure in relation to critical developmental periods and should take into account the dynamic interplay between gene and environment by using genetically informed designs.
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:   Assisted reproductive technology

ASD

:   Autism spectrum disorder

C/S

:   Cesarean section

DZ

:   Dizygotic

EMB

:   Extreme male brain

FMRP

:   Fragile X mental retardation protein

FPE

:   Female protective effect
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:   Gamma-aminobutyric acid

HIE

:   Hypoxic-ischemic encephalopathy

MMR

:   Mumps, measles, and rubella
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:   Methylene tetrahydrofolate reductase
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:   Mammalian target of rapamycin
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:   Monozygotic
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:   Prostaglandin E2
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